Citius Pharmaceuticals, Inc. financial data

Symbol
CTXR on Nasdaq
Location
Cranford, NJ
Fiscal year end
30 September
Latest financial report
10-Q - Q2 2025 - 12 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 41% % -93%
Quick Ratio 30% %
Debt-to-equity 81% % 505%
Return On Equity -23% % 44%
Return On Assets -20% % 27%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17,012,191 shares -91%
Common Stock, Shares, Outstanding 14,475,029 shares -92%
Common Stock, Value, Issued $14,475 USD -92%
Weighted Average Number of Shares Outstanding, Basic 11,006,896 shares 58%
Weighted Average Number of Shares Outstanding, Diluted 11,006,896 shares 58%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $40,914,888 USD 245%
General and Administrative Expense $20,121,094 USD 19%
Operating Income (Loss) $41,138,777 USD -0.17%
Nonoperating Income (Expense) $1,710 USD -100%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $41,137,067 USD -9.1%
Income Tax Expense (Benefit) $144,000 USD 0%
Net Income (Loss) Attributable to Parent $11,511,505 USD -35%
Earnings Per Share, Basic -4 USD/shares 49%
Earnings Per Share, Diluted -4 USD/shares 49%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $6,089,126 USD -66%
Inventory, Net $17,208,967 USD
Assets, Current $24,611,269 USD -12%
Property, Plant and Equipment, Net $275 USD -90%
Operating Lease, Right-of-Use Asset $880,732 USD 194%
Goodwill $9,346,796 USD 0%
Other Assets, Noncurrent $102,184,858 USD
Assets $127,676,859 USD 32%
Accounts Payable, Current $10,094,042 USD 507%
Employee-related Liabilities, Current $3,710,041 USD 118%
Accrued Liabilities, Current $8,523,675 USD 1448%
Liabilities, Current $51,842,452 USD 1149%
Deferred Income Tax Liabilities, Net $7,506,520 USD 14%
Operating Lease, Liability, Noncurrent $766,957 USD 808%
Liabilities $60,115,929 USD 456%
Retained Earnings (Accumulated Deficit) $230,844,841 USD -21%
Stockholders' Equity Attributable to Parent $65,058,550 USD -24%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $67,560,930 USD -22%
Liabilities and Equity $127,676,859 USD 32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,725,852 USD 23%
Net Cash Provided by (Used in) Financing Activities $2,574,051 USD
Common Stock, Shares Authorized 250,000,000 shares -38%
Common Stock, Shares, Issued 14,475,029 shares -92%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6,089,126 USD -66%
Deferred Tax Assets, Valuation Allowance $53,821,000 USD 20%
Operating Lease, Liability $881,651 USD 176%
Lessee, Operating Lease, Liability, to be Paid $1,073,028 USD 217%
Operating Lease, Liability, Current $114,694 USD -51%
Lessee, Operating Lease, Liability, to be Paid, Year Two $232,827 USD 985%
Lessee, Operating Lease, Liability, to be Paid, Year One $192,740 USD -24%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) $264,240 USD 84%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $191,377 USD 935%
Lessee, Operating Lease, Liability, to be Paid, Year Three $237,686 USD
Deferred Tax Assets, Operating Loss Carryforwards $39,888,000 USD 14%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $242,545 USD
Additional Paid in Capital $295,888,916 USD 7.2%
Share-based Payment Arrangement, Expense $12,817,608 USD 161%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%